COO, CLO, Compliance Officer
Jennifer Bush is the Chief Operating Officer, Chief Legal Officer, Corporate Secretary, and Compliance Officer of Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company focused on off‑the‑shelf NK cell therapies.[[4]](https://investors.artivabio.com/News-and-Events/news/news-details/2024/Artiva-Biotherapeutics-Readies-for-the-Next-Phase-of-Growth-with-the-Appointment-of-Neha-Krishnamohan-as-CFO-and-EVP-Corporate-Development-and-Promotion-of-Jennifer-Bush-to-Chief-Operating-Officer/default.aspx)[[8]](https://www.secform4.com/insider-trading/1817241.htm) She joined Artiva in 2020 as General Counsel, was promoted to Chief Legal & People Officer in 2021, and in April 2024 was elevated to Chief Operating Officer while retaining her senior legal and compliance responsibilities.[[2]](https://www.artivabio.com/post-member/jennifer-bush/)[[4]](https://investors.artivabio.com/News-and-Events/news/news-details/2024/Artiva-Biotherapeutics-Readies-for-the-Next-Phase-of-Growth-with-the-Appointment-of-Neha-Krishnamohan-as-CFO-and-EVP-Corporate-Development-and-Promotion-of-Jennifer-Bush-to-Chief-Operating-Officer/default.aspx) As COO, she leads Artiva’s legal, people and culture, information technology, patient engagement, community access, and broader operational and governance initiatives.[[2]](https://www.artivabio.com/post-member/jennifer-bush/)[[4]](https://investors.artivabio.com/News-and-Events/news/news-details/2024/Artiva-Biotherapeutics-Readies-for-the-Next-Phase-of-Growth-with-the-Appointment-of-Neha-Krishnamohan-as-CFO-and-EVP-Corporate-Development-and-Promotion-of-Jennifer-Bush-to-Chief-Operating-Officer/default.aspx) Recent SEC filings list her as COO, CLO, Compliance Officer and disclose her insider equity transactions in Artiva shares.[[3]](https://www.streetinsider.com/SEC+Filings/Form+4+Artiva+Biotherapeutics,+For:+May+19+Filed+by:+Bush+Jennifer/26523450.html)[[8]](https://www.secform4.com/insider-trading/1817241.htm)
Bush is a senior legal and business executive with more than 20 years of experience advising and leading public and private companies in technology and life sciences.[[1]](https://theorg.com/org/artiva-biotherapeutics/org-chart/jennifer-bush)[[2]](https://www.artivabio.com/post-member/jennifer-bush/) Before Artiva, she served as Senior Vice President, General Counsel, Corporate Secretary, and Compliance Officer at tissue‑engineering company Organovo, where she oversaw legal, human resources, regulatory, and government relations functions.[[1]](https://theorg.com/org/artiva-biotherapeutics/org-chart/jennifer-bush)[[2]](https://www.artivabio.com/post-member/jennifer-bush/) Earlier, she held a senior legal role at Broadcom and spent about a decade as a commercial and intellectual property litigator at Fish & Richardson, representing life science, medical device, and software companies.[[1]](https://theorg.com/org/artiva-biotherapeutics/org-chart/jennifer-bush)[[2]](https://www.artivabio.com/post-member/jennifer-bush/) Bush serves on the board of directors of the San Diego Association of Corporate Counsel and is active in professional governance organizations.[[1]](https://theorg.com/org/artiva-biotherapeutics/org-chart/jennifer-bush)[[2]](https://www.artivabio.com/post-member/jennifer-bush/) She earned a bachelor’s degree in history and Latin American studies from Princeton University and a J.D. from Yale Law School.[[1]](https://theorg.com/org/artiva-biotherapeutics/org-chart/jennifer-bush)[[2]](https://www.artivabio.com/post-member/jennifer-bush/)
View full insider profile →
Discussion